Bluesky Facebook Reddit Email

RAMP1 protects hepatocytes against ischemia-reperfusion injury by inhibiting the ERK/YAP pathway

04.23.24 | Xia & He Publishing Inc.

Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.


Hepatic ischemia-reperfusion injury (HIRI) is a prevalent complication of liver transplantation, partial hepatectomy, and severe infection, necessitating the development of more effective clinical strategies. Receptor activity–modifying protein 1 (RAMP1), a member of the G protein–coupled receptor adapter family, has been implicated in numerous physiological and pathological processes. The study aimed to investigate the pathogenesis of RAMP1 in HIRI.

We established a 70% liver ischemia-reperfusion model in RAMP1 knockout (KO) and wild-type mice. Liver and blood samples were collected after 0, 6, and 24 h of hypoxia/reperfusion. Liver histological and serological analyses were performed to evaluate liver damage. We also conducted in-vitro and in-vivo experiments to explore the molecular mechanism underlying RAMP1 function.

Liver injury was exacerbated in RAMP1-KO mice compared with the sham group, as evidenced by increased cell death and elevated serum transaminase and inflammation levels. HIRI was promoted in RAMP1-KO mice via the induction of hepatocyte apoptosis and inhibition of proliferation. The absence of RAMP1 led to increased activation of the extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway and yes-associated protein (YAP) phosphorylation, ultimately promoting apoptosis. SCH772984, an ERK/MAPK phosphorylation inhibitor, and PY-60, a YAP phosphorylation inhibitor, reduced apoptosis in in-vitro and in-vivo experiments.

Our findings suggest that RAMP1 protects against HIRI by inhibiting ERK and YAP phosphorylation signal transduction, highlighting its potential as a therapeutic target for HIRI and providing a new avenue for intervention.

https://www.xiahepublishing.com/2310-8819/JCTH-2023-00339

The study was recently published in the Journal of Clinical and Translational Hepatology .

Follow us on X: https://twitter.com/xiahepublishing

Follow us on LinkedIn: https://www.linkedin.com/company/xia&he-publishing-inc/

Journal of Clinical and Translational Hepatology

10.14218/JCTH.2023.00339

RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

29-Feb-2024

Keywords

Article Information

Contact Information

Shelly Zhang
Xia & He Publishing Inc.
shelly109@foxmail.com

Source

How to Cite This Article

APA:
Xia & He Publishing Inc.. (2024, April 23). RAMP1 protects hepatocytes against ischemia-reperfusion injury by inhibiting the ERK/YAP pathway. Brightsurf News. https://www.brightsurf.com/news/L7VOGRO8/ramp1-protects-hepatocytes-against-ischemia-reperfusion-injury-by-inhibiting-the-erkyap-pathway.html
MLA:
"RAMP1 protects hepatocytes against ischemia-reperfusion injury by inhibiting the ERK/YAP pathway." Brightsurf News, Apr. 23 2024, https://www.brightsurf.com/news/L7VOGRO8/ramp1-protects-hepatocytes-against-ischemia-reperfusion-injury-by-inhibiting-the-erkyap-pathway.html.